1. Opthea Limited completed the final week 52 patient visit in COAST and ShORe, two phase III pivotal trials for wet AMD treatment.
2. The primary endpoint for both trials is the mean change in best-corrected visual acuity (BCVA) from baseline to week 52 for sozinibercept combination therapy compared with anti-VEGF-A monotherapy.
3. Patients will be treated for an additional year beyond week 52 to assess extended safety and tolerability.
4. With the FDA's Fast Track Designation, Opthea's phase III program aims to enable sozinibercept to be approved for use in combination with any anti-VEGF-A therapy in wet AMD patients.
5. The topline results from both trials are expected in early and mid-CY25.

Source: Ophthalmology Management